IN2015DN02907A - - Google Patents

Info

Publication number
IN2015DN02907A
IN2015DN02907A IN2907DEN2015A IN2015DN02907A IN 2015DN02907 A IN2015DN02907 A IN 2015DN02907A IN 2907DEN2015 A IN2907DEN2015 A IN 2907DEN2015A IN 2015DN02907 A IN2015DN02907 A IN 2015DN02907A
Authority
IN
India
Prior art keywords
disintegrating
particle composition
tablet
acid
present
Prior art date
Application number
Other languages
English (en)
Inventor
Hiramura Takahiro
Ikura Kiyoshi
Ishikawa Sae
Okabayashi Tomohito
Hashikawa Naohiro
Morita Tetsuro
Ikeda Kimiko
Original Assignee
Daicel Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daicel Corp filed Critical Daicel Corp
Publication of IN2015DN02907A publication Critical patent/IN2015DN02907A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Inorganic Chemistry (AREA)
IN2907DEN2015 2012-09-20 2013-09-13 IN2015DN02907A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012206897 2012-09-20
PCT/JP2013/074823 WO2014046035A1 (ja) 2012-09-20 2013-09-13 酸型カルボキシメチルセルロース及び結晶セルロースを含む崩壊性粒子組成物及び該組成物を含む口腔内崩壊錠剤

Publications (1)

Publication Number Publication Date
IN2015DN02907A true IN2015DN02907A (ko) 2015-09-11

Family

ID=50341348

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2907DEN2015 IN2015DN02907A (ko) 2012-09-20 2013-09-13

Country Status (8)

Country Link
US (1) US10292934B2 (ko)
EP (1) EP2898899B1 (ko)
JP (1) JP6230539B2 (ko)
KR (1) KR102114487B1 (ko)
CN (1) CN104010663B (ko)
IN (1) IN2015DN02907A (ko)
TW (1) TWI639446B (ko)
WO (1) WO2014046035A1 (ko)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015005241A1 (ja) * 2013-07-06 2015-01-15 株式会社ダイセル 超速崩壊錠剤及びその製造方法
CN105555262A (zh) * 2013-09-27 2016-05-04 株式会社大赛璐 含有崩解性颗粒组合物的口腔内崩解片剂
EP3050575B1 (en) 2013-09-27 2020-05-06 Daicel Corporation Disintegrating particle composition produced by two-stage wet granulation process, and intraorally disintegrating tablet containing same composition
JP2017226600A (ja) * 2014-10-16 2017-12-28 株式会社ダイセル 超速崩壊錠剤
AU2015351685B2 (en) 2014-11-24 2020-07-16 Daicel Corporation Disintegrative particle composition including pulverized lactose or granulated lactose
JP6513702B2 (ja) * 2014-12-25 2019-05-15 株式会社ダイセル 超速崩壊錠剤及びその製造方法
TWI695722B (zh) * 2015-06-29 2020-06-11 日商大賽璐股份有限公司 固態製劑之外層用組成物及含有該外層用組成物之易服用性固態製劑
ES2607715B1 (es) 2015-10-01 2018-01-17 Solutex Na, Lcc Proceso para la preparación y estabilización de emulsiones con omega-3 mediante redes cristalinas isométricas de derivados de celulosa
EP3406241A4 (en) * 2016-01-18 2019-06-26 Daicel Corporation INTRAORAL RESISTANT DISTILLANT SOLUBLE PREPARATION, METHOD FOR THE MANUFACTURE THEREOF, AND POWDER COMPOSITION USED IN THE SAID MANUFACTURING METHOD
JP2019156723A (ja) * 2018-03-07 2019-09-19 大原薬品工業株式会社 圧縮成形性に優れた賦形剤を用いる、浸透膨潤型口腔内崩壊錠
JP7036856B2 (ja) * 2019-03-28 2022-03-15 日本ケミファ株式会社 口腔内崩壊錠
WO2021090421A1 (ja) * 2019-11-07 2021-05-14 旭化成株式会社 セルロース組成物、錠剤及び口腔内崩壊錠
PT4061328T (pt) 2019-11-22 2024-04-08 Biohorm S L Comprimidos orodispersíveis de zonisamida

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2851453A (en) 1954-08-09 1958-09-09 Smith Kline French Lab Cellulose derivative product, compositions comprising the same and their preparation
JPH10182436A (ja) 1996-10-31 1998-07-07 Takeda Chem Ind Ltd 固形医薬製剤
JP2000273039A (ja) * 1999-01-20 2000-10-03 Taisho Pharmaceut Co Ltd 口腔内崩壊性組成物
JP2000290172A (ja) * 1999-04-09 2000-10-17 Earth Chem Corp Ltd 発泡タブレット
JP4284017B2 (ja) * 2000-10-06 2009-06-24 武田薬品工業株式会社 固形製剤
AU2001294192A1 (en) * 2000-10-06 2002-04-22 Takeda Chemical Industries Ltd. Solid preparations
JP4551627B2 (ja) 2003-02-28 2010-09-29 東和薬品株式会社 口腔内崩壊錠剤の製造方法
WO2007018192A1 (ja) 2005-08-10 2007-02-15 Shionogi & Co., Ltd. 口腔内崩壊錠剤
JP5123517B2 (ja) 2005-11-14 2013-01-23 帝人ファーマ株式会社 アンブロキソール口腔内速崩性錠剤
JP5766899B2 (ja) * 2007-04-11 2015-08-19 ニプロ株式会社 口腔内崩壊剤及びその製造方法
JP2008285434A (ja) 2007-05-16 2008-11-27 Taisho Pharm Ind Ltd 口腔内速崩壊錠
CN101707930B (zh) 2007-06-06 2013-10-30 巴斯夫欧洲公司 用于制备快速崩解的片剂的药物配制剂
JP4989733B2 (ja) 2008-02-13 2012-08-01 大日本住友製薬株式会社 口腔内崩壊錠
JP5674666B2 (ja) 2009-08-11 2015-02-25 富士化学工業株式会社 崩壊性粒子組成物及び口腔内速崩壊錠
KR20120046766A (ko) * 2009-08-11 2012-05-10 다이닛본 스미토모 세이야꾸 가부시끼가이샤 2종 이상의 입자들을 함유하는 구강 속붕해성 정제
US20110150989A1 (en) 2009-12-22 2011-06-23 Mallinkckrodt Inc. Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
JP6073543B2 (ja) 2010-07-08 2017-02-01 沢井製薬株式会社 ロラタジン含有口腔内崩壊錠の製造方法
JP6245677B2 (ja) 2012-01-20 2017-12-13 ニプロ株式会社 口腔内崩壊錠
KR101707938B1 (ko) 2012-03-29 2017-02-17 주식회사 다이셀 산형(酸型) 카르복시 메틸 셀룰로오스를 포함하는 붕해성 입자 조성물의 제조 방법, 및 상기 조성물과 상기 조성물을 포함하는 구강내 붕해 정제

Also Published As

Publication number Publication date
CN104010663B (zh) 2021-02-19
US20150238424A1 (en) 2015-08-27
KR102114487B1 (ko) 2020-05-22
EP2898899A4 (en) 2016-03-16
TWI639446B (zh) 2018-11-01
KR20150056636A (ko) 2015-05-26
EP2898899A1 (en) 2015-07-29
CN104010663A (zh) 2014-08-27
JP6230539B2 (ja) 2017-11-15
TW201417843A (zh) 2014-05-16
EP2898899B1 (en) 2019-09-11
US10292934B2 (en) 2019-05-21
JPWO2014046035A1 (ja) 2016-08-18
WO2014046035A1 (ja) 2014-03-27

Similar Documents

Publication Publication Date Title
IN2015DN02907A (ko)
EA033343B1 (ru) Соединения, ингибирующие rip2-киназу, фармацевтическая композиция на их основе и их применение для лечения заболеваний, опосредуемых rip2-киназой
PH12015501385A1 (en) Autotaxin inhibitors
IN2015DN01156A (ko)
MY189427A (en) Pyrazolyl quinoxaline kinase inhibitors
EP4036240A3 (en) Transduction buffer
GEP20156347B (en) Benzodioxane inhibitors of leukotriene production
UA109661C2 (uk) Фармацевтична композиція співкристалів трамадолу і коксибів
TN2012000534A1 (en) Pyrazole compounds as sigma receptor inhibitors
SG171542A1 (en) Pharmaceutical composition comprising a strontium salt, vitamin d and a cyclodextrin
MX2016000794A (es) Composiciones farmaceuticas de pancreatina de potencia alta.
MY195343A (en) A Novel Phtalazinone Derivatives and Manufacturing Process Thereof
WO2011048563A3 (en) Orally disintegrating tablets of betahistine
IN2013MU03583A (ko)
WO2011104652A3 (en) Veterinary compositions
TN2012000507A1 (en) Enteric tablet
MX2016000480A (es) Composiciones farmaceuticas de pancreatina de alta potencia.
MX2012001691A (es) Composiciones de linaclotida que se desintegran oralmente.
CA2890042C (en) 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives
MX2015000179A (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
IN2014DN03010A (ko)
IN2015DN02296A (ko)
PL2293791T3 (pl) Kompozycje farmaceutyczne entakaponu współ-mikronizowanego z alkoholami cukrowymi
WO2010086617A3 (en) Phosphoantigens for the treatment of burkholderia infections
WO2014122671A3 (en) Solid oral compositions of saxagliptin